Objective This study assessed the effects of semaglutide on body weight, cardiometabolic
risk factors, and glycemic status in individuals categorized by baseline BMI with or without …

Background Obesity is a global health challenge with few pharmacologic options. Whether
adults with obesity can achieve weight loss with once-weekly semaglutide at a dose of 2.4 …

Aims Evaluate the effects of once‐weekly subcutaneous semaglutide 2.4 mg on
cardiometabolic risk factors in people with overweight/obesity without diabetes in the STEP …

Background: The 2-year efficacy and safety of once-weekly (OW) subcutaneous semaglutide
2.4 mg vs placebo in adults with overweight/obesity was assessed in the STEP 5 phase 3 …

Abstract Objective In the Semaglutide Treatment Effect in People with obesity (STEP) trials,
once‐weekly subcutaneous semaglutide 2.4 mg plus lifestyle intervention reduced body …

Abstract Background/Objective There are limited real-world studies assessing semaglutide
weight loss and associated comorbidity and metabolic outcomes over periods≥ 6 months …

Aims To evaluate the efficacy and safety of oral semaglutide versus comparators by patient
characteristic subgroups in patients with type 2 diabetes. Materials and Methods Change …

OBJECTIVE To determine whether semaglutide slows progression of glycemia in people
with cardiovascular disease and overweight or obesity but without diabetes. RESEARCH …

Background Semaglutide, a glucagon-like peptide-1 receptor agonist, has been shown to
reduce the risk of adverse cardiovascular events in patients with diabetes. Whether …

Purpose This meta-analysis aimed to assess the efficacy and safety of once-weekly
semaglutide among adults with overweight or obesity. Methods We searched multiple …